Véronique Kemmel

5PUBLICATIONS
7CO-AUTHORS
Major global burdens of diseaseCentral nervous systemMolecular targetsPredictive and prognostic markers
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (5)

|Jun 26, 2026
The Hydroxyurea Absorption Phenotype: A Key PK/PD Determinant in Sickle Cell Disease Treatment.

|Nov 27, 2021
Blood-Brain Barrier Permeability: Is 5-Hydroxytryptamine Receptor Type 4 a Game Changer?

Guillaume Becker, Sylvia Da Silva, Amelia-Naomi Sabo

|Apr 03, 2021
Sirolimus Pharmacokinetics Variability Points to the Relevance of Therapeutic Drug Monitoring in Pediatric Oncology.

Amelia-Naomi Sabo, Sarah Jannier, Guillaume Becker

|Oct 23, 2020
SFCE-RAPIRI Phase I Study of Rapamycin Plus Irinotecan: A New Way to Target Intra-Tumor Hypoxia in Pediatric Refractory Cancers.

Sarah Jannier, Véronique Kemmel, Consuelo Sebastia Sancho

|Oct 19, 2019
Optimizing Hydroxyurea Treatment for Sickle Cell Disease Patients: The Pharmacokinetic Approach.

Charlotte Nazon, Amelia-Naomi Sabo, Guillaume Becker

Pageof 1

Frequent Collaborators

1 joint publications

Amelia-Naomie Sabo

1 joint publications

Didier Frappaz

1 joint publications

Anne Isabelle Bertozzi

1 joint publications

Sarah Jannier